Log in
NASDAQ:INGN

Inogen Stock Forecast, Price & News

$28.77
+0.16 (+0.56 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$27.91
Now: $28.77
$29.11
50-Day Range
$27.01
MA: $30.20
$34.90
52-Week Range
$26.57
Now: $28.77
$76.89
Volume507,685 shs
Average Volume369,511 shs
Market Capitalization$634.84 million
P/E Ratio95.90
Dividend YieldN/A
Beta0.78
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Read More
Inogen logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$361.94 million
Cash Flow$1.82 per share
Book Value$15.67 per share

Profitability

Net Income$20.95 million

Miscellaneous

Employees1,020
Market Cap$634.84 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$28.77
+0.16 (+0.56 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inogen (NASDAQ:INGN) Frequently Asked Questions

How has Inogen's stock been impacted by COVID-19?

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INGN stock has decreased by 29.2% and is now trading at $28.77.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Inogen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Inogen
.

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Inogen
.

How were Inogen's earnings last quarter?

Inogen Inc (NASDAQ:INGN) released its quarterly earnings results on Tuesday, August, 4th. The medical technology company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.20. The medical technology company had revenue of $71.70 million for the quarter, compared to the consensus estimate of $79.96 million. Inogen had a net margin of 1.96% and a return on equity of 2.68%. The company's revenue for the quarter was down 29.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.45 EPS.
View Inogen's earnings history
.

What price target have analysts set for INGN?

4 analysts have issued 12 month price objectives for Inogen's shares. Their forecasts range from $35.00 to $75.00. On average, they anticipate Inogen's stock price to reach $51.67 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price.
View analysts' price targets for Inogen
.

Who are some of Inogen's key competitors?

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intel (INTC), Netflix (NFLX) and First Solar (FSLR).

Who are Inogen's key executives?

Inogen's management team includes the following people:
  • Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)
  • Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)
  • Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 53)
  • Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40)

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.98%), Goldman Sachs Group Inc. (1.67%), Bamco Inc. NY (1.63%), Two Sigma Advisers LP (1.26%), Rockefeller Capital Management L.P. (1.24%) and Riverbridge Partners LLC (1.19%). Company insiders that own Inogen stock include Brenton Taylor, Heath Lukatch, Loren L Mcfarland, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends for Inogen
.

Which institutional investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Balyasny Asset Management LLC, Beacon Investment Advisory Services Inc., Vanguard Group Inc., Russell Investments Group Ltd., Two Sigma Advisers LP, Bank of America Corp DE, and Rockefeller Capital Management L.P..
View insider buying and selling activity for Inogen
.

Which institutional investors are buying Inogen stock?

INGN stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Assenagon Asset Management S.A., Bamco Inc. NY, Grantham Mayo Van Otterloo & Co. LLC, Engineers Gate Manager LP, Bellevue Group AG, Hussman Strategic Advisors Inc., and Goldman Sachs Group Inc.. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen
.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $28.77.

How big of a company is Inogen?

Inogen has a market capitalization of $634.84 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.